The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma
The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma
美國食品藥品管理局已向MAIA Biotechnology的主要資產THIO（一種癌症端粒靶向劑）授予孤兒藥稱號，用於治療膠質母細胞瘤
The FDA Has Granted Orphan Drug Designation To MAIA Biotechnology's Lead Asset THIO, A Cancer Telomere-targeting Agent, For The Treatment Of Glioblastoma
美國食品藥品管理局已向MAIA Biotechnology的主要資產THIO（一種癌症端粒靶向劑）授予孤兒藥稱號，用於治療膠質母細胞瘤